Trevena, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing innovative pharmaceutical solutions for individuals suffering from central nervous system disorders. Its pipeline features several promising drug candidates: OLINVYK (Oliceridine) injection: A G protein-biased mu-opioid receptor (MOR) ligand engineered to manage acute pain ranging from moderate to severe. TRV027: Aimed at addressing acute lung injury, which contributes to acute respiratory distress syndrome (ARDS) and abnormal blood clotting in patients with COVID-19.
| Date | Est. | Actual | |
|---|---|---|---|
| Nov 7, 2024 | -$7.32 | -$5.79 | Beat |
| Aug 8, 2024 | -$9.25 | -$5.75 | Beat |
| May 15, 2024 | -$0.47 | -$9.00 | Miss |
| Mar 28, 2024 | -$0.38 | -$1.06 | Miss |
| Nov 14, 2023 | -$0.15 | -$14.25 | Miss |